EVALUATION OF HYDROLYZED ALLERGEN PREPARATIONS
20210123905 · 2021-04-29
Assignee
Inventors
- Cecile Pâques (Lierneux, BE)
- Thierry Legon (Roosbeek, BE)
- Sabine Pirotton (Bruxelles, BE)
- Nicolas Bovy (Grâce-Hollogne, BE)
Cpc classification
International classification
Abstract
A method for the evaluation of a hydrolyzed allergen preparation comprising the steps of: bringing the preparation into contact with a human blood sample—measuring proliferation of IL10 producing regulatory B-cells, wherein proliferation indicates suitability of the preparation.
Claims
1. A method for the evaluation of a hydrolyzed allergen preparation comprising the steps of: bringing the preparation into contact with a human blood sample measuring proliferation of IL10 producing regulatory B-cells, wherein proliferation indicates suitability of the preparation.
2. The method of claim 1, wherein the method is for the evaluation of the suitability of the hydrolyzed allergen preparation for the treatment or prevention of IgE mediated allergy.
3. The method of claim 1, wherein tec cation is a quality control within a production process.
4. The method of claim 1, wherein the evaluation is a screening in drug development.
5. The method of claim 1, wherein the method further comprises: bringing an unhydrolyzed allergen preparation into contact with a second identical blood sample measuring proliferation of IL10 producing regulatory B-cells comparing proliferation in the two samples, wherein a higher proliferation in the sample being in contact with the hydrolyzed allergen preparation than in the sample in contact with the unhydrolyzed allergen indicates suitability.
6. The method of claim 1, wherein the blood sample is from a subject being allergic to the allergen.
7. The method of claim 1, wherein the blood sample is from a subject being non-allergic to the allergen.
8. The method of claim 1, wherein the allergens is selected from allergens are selected among pollen allergens, milk allergens, venom allergens, egg allergens, weed allergens, grass allergens, tree allergens, shrub allergens, flower allergens, vegetable allergens, grain allergens, fungi allergens, fruit allergens, berry allergens, nut allergens, seed allergens, bean allergens, fish allergens, shellfish allergens, seafood allergens, meat allergens, spices allergens, insect allergens, mite allergens, mould allergens, animal allergens, pigeon tick allergens, worm allergens, soft coral allergens, animal dander allergens, nematode allergens, allergens of Hevea brasiliensis.
9. The method of claim 1, wherein the method comprises steps for preparing the hydrolyzed allergens: a) extracting a natural source of allergens comprising allergenic proteins to form an extract, b) purifying of said extract to remove non-protein components to form a purified extract, c) denaturing said purified extract to form a purified denatured extract, d) hydrolyzing the purified denatured extract to form hydrolyzed allergen peptides.
10. The method of claim 1, wherein the method comprises steps for preparing the hydrolyzed allergens a) extracting a source of allergens comprising allergenic proteins to fort an extract, b) purifying the extract to remove non-protein components to form a purified extract, c) denaturing the purified extract with a first denaturing agent to form a purified denatured extract, d) refining the purified denatured e trac to remove impurities to form a refined denatured extract, e) denaturing the refined denatured extract with a second denaturing agent to form denatured allergen mixture, and f) hydrolyzing the denatured allergen mixture to form the hydrolyzed allergen peptides.
11. The method of claim 1, wherein the IL10 producing regulatory B-cells are CD19.sup.30 IL10.sup.+ B-cells.
12. The method of claim 1, wherein the IL10 producing regulatory B-cells are CD19.sup.+CD27.sup.+IL10.sup.+ B-cells.
13. The method of claim 1, wherein the IL10 producing regulatory B-cells are CD19.sup.+CD5.sup.+CD38.sup.hi CD24.sup.hiIL10.sup.+ B-cells.
14. The method of claim 1, wherein the IL10 producing regulatory B-cells are CD19.sup.+CD5.sup.+CD38.sup.intCD24.sup.intIL10.sup.+ B-cells.
Description
DESCRIPTION OF FIGURES
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051] All references cited herein are incorporated by reference to the full extent to which the incorporation is not inconsistent with the express teachings herein.
[0052] The invention is further explained by the following, non-limiting examples.
EXAMPLES
Example 1
Preparation of Grass Pollen (Lolium perenne) Peptides
Example 1.1
Extraction
[0053] 1% (w/v) pollen (Lolium perenne from ALLERGON) was added to sodium bicarbonate (12.5 mM) and incubated 2 h under stirring. The solution was then clarified and filtrated by adding celite (ACROS) at 2% (w/v) and passing through a 0.2 μm filter. This sample constitutes the crude extract.
[0054] The presence of allergens in the extract was analyzed by western blotting using pollen allergic patient sera. IgG and IgE epitopes are visualized with anti-human IgG or IgE antibodies.
[0055] The said crude extract was acidified to pH 3.0 and Tween 20 (0.1%, v/v) was added. This sample constitutes the acidified extract.
Example 1.2
Purification of Allergen Proteins
[0056] The allergen extract was purified by:
[0057] Cation exchange chromatography [0058] A sartobind S.sup.− membrane (SARTORIUS) was equilibrated with 28× Bed volume (Bv) of sodium bicarbonate 12.5 mM, citrate 30 mM, pH 3.0, Tween 20 0.1% (v/v). The said acidified extract was loaded on the equilibrated membrane. The column was washed first with 35× By of sodium bicarbonate 12.5 mM, citrate 30 mM, pH 3.0, Tween 20 0.1% (v/v) and then washed with 42× Bv of sodium bicarbonate 12.5 mM, citrate 30 mM, pH 3.0. The proteins were eluted with carbonate 0.1 M, sodium chloride 0.5 M, pH 9.15. The presence of proteins was followed the OD at 280 nm. The fractions of interest were pooled.
[0059] Ammonium sulfate precipitation [0060] This step was performed at 0-4° C. [0061] A quantity of ammonium sulfate to reach 90% of saturation was added to the product under stirring. The stirring was stopped after the complete dissolution of the salt. The suspension was incubated overnight and centrifuged 2 times during 15 min at 10,000 g. The supernatant was each time carefully discarded.
[0062] Denaturation [0063] The pellets were resuspended at 9 mg/ml in urea 6 M, DTT 10 mM, Tris.HCl 0.1 M, pH 8.0 and incubated at 37° C. for 1 h.
[0064] Size exclusion chromatography on G25 resin (fine Sephadex from AMERSHAM) [0065] The denatured sample was loaded on the column and the proteins were eluted with Tris.HCl 25 mM, urea 1.5 M, pH 8.0.
[0066] The presence of proteins was followed by the OD measurement at 280 nm The fractions of interest were pooled to constitute the purified denaturated allergen extract.
[0067] The purified allergen extract was further analyzed. The protein content (BCA Assay) and the dry weight were determined in order to evaluate the protein purity. The purification efficiency was also followed by the removal of carbohydrates (Orcinol test) and by the decrease of the ratio OD.sub.260/OD.sub.280.
TABLE-US-00001 TABLE 1 Removal of non-protein components to form a purified extract Ratio protein/ Ratio OD.sub.260/ Ratio carbohydrates/ dry weight OD.sub.280 proteins Crude extract 16% 1.3 400% Purified extract 85% 0.75 17%
[0068] As shown in table 1, the purification process allows
[0069] The increase of the percentage of proteins in the extract from ˜15% to 80%
[0070] The OD.sub.260/OD.sub.280 ratio to tends towards 0.5 characterizing a pure protein
[0071] A significant removal of carbohydrates (the residual content could represent the carbohydrate moiety of the proteins).
Example 1.3
Hydrolysis of Denatured Allergen Extract
[0072] The extract was hydrolyzed using the following protocol:
[0073] The said purified allergen extract was acidified to pH 2.0. The digestion was performed at 2.5 mg/ml of pollen proteins and 1 Eu. Ph. U of pepsin (MERCK) for 337 mg of proteins, at 37° C., during 2 h.
Example 1.4
Purification
[0074] In order to eliminate the peptides with a MW≥10,000 Da and MW≤1,000 Da, the hydrolyzate was purified by
[0075] Size exclusion chromatography on G50 resin (fine Sephadex from AMERSHAM) [0076] 16.5% (v/v) of isopropanol and 0.1 M of NaCl were added to the hydrolyzate. This sample was immediately loaded on a G50 column. The peptides were eluted and the fractions containing the peptides (MW≤10 kDa) were pooled 6.
[0077] Diafiltration on 1kDa membrane (ultrafiltration cassette Omega PES from PALL) [0078] The peptides were concentrated 10×, diafiltrated against 10 volumes of Tris.HCl 50 mM pH 7.4 and finally concentrated 2.5×. This sample constitutes the purified allergen hydrolyzate.
[0079] The efficiency of the purification was controlled by size exclusion HPLC. A BioSep-SEC S2000 column (PHENOMENEX) was equilibrated with Na2HPO.sub.4 50 mM—SDS 0.5% (w/v) pH 6.8 at a flow rate of 1 ml/min. The peptides were detected at 214 nm.
[0080] Three examples of size exclusion chromatography are shown in
Example 2
Preparation of Peanut (Arachis hypogaea) Peptides
Example 2.1
Extraction of Peanut Allergens
[0081] A mix of three peanut types (Arachis hypogaea species Runner, Virginia and Spanish) were peeled, grinded and mixed. A 2% (w/v) of the mix of peanuts was added to sodium phosphate (12.5 mM) and incubated 1 h under stirring at room temperature. The solution was then clarified and filtrated by adding Celite at 2% (w/v) and passing through a 0.45 μm filter. This sample constitutes the crude protein extract.
[0082] The presence of allergens in the crude protein extract was confirmed by Western-Blot using peanut allergic patient sera.
Example 2.2
Purification of Peanut Allergen Proteins
[0083] The allergen extract was purified by: [0084] Trichloroacetic acid precipitation
[0085] This step was performed at room temperature (20 to 25° C.).
[0086] 10% (w/v) trichloroacetic acid was added to the product under stirring. Then, the precipitated extract was centrifuged during 15 minutes at 10.000 g. The supernatant was carefully discarded. [0087] First Denaturation
[0088] The pellets were resuspended at 25 mg/ml in 8 M Urea, 0.1 M Tris-HCl, pH 8.0 and 80 mM DTT were added. The solution was incubated at 37° C. for 1 h. [0089] Size exclusion chromatography on a G25 resin column (fine Sephadex from GE Healthcare)
[0090] The purified denatured extract was immediately loaded on the column and the proteins were eluted with 2 M Urea, 0.1 M Tris-HCl, pH 8.0.
[0091] The presence of proteins was followed by the absorbance at 280 nm. The fractions of interest were pooled to constitute the refined denatured extract.
[0092] The refined denatured extract was further analyzed by SDS-PAGE and by Western Blotting using peanut allergic patient sera. [0093] Second Denaturation:
[0094] 8 M urea and 40 mM TCEP were added to the refined denatured extract. Then, the pH was adjusted to 2.5. The solution was incubated at 37° C. for 1 h.
Example 2.3
Hydrolysis of the Denatured Peanut Allergens
[0095] The denatured allergens were hydrolyzed using the following protocol:
[0096] The denatured allergen mixture was diluted 4-fold with 10 mM HCl and acidified with HCl 6 N to pH 2.0. The protein hydrolysis was performed with 16 Eu.Ph.0 of pepsin for 100 mg of proteins at 37° C., during 2 h. The hydrolysis was then stopped by raising the pH to 10.0 with NaOH solution.
Example 2.4
Purification of Hydrolyzed Peanut Allergens
[0097] In order to eliminate the peptides with a MW 10.000 Da and MW 1.000 Da, the hydrolyzed allergens were purified by: [0098] Size exclusion chromatography on G50 resin (fine Sephadex from GE Healthcare). After increasing pH, the hydrolyzed allergens were rapidly loaded on the G50 column. The peptides were eluted with 2 M Urea, 0.1 M Tris-HCl, pH 9.5. The elution was followed by the absorbance at 280 nm. The fractions containing the peptides (MW 10 kDa) were. [0099] Diafiltration on 1 kDa membrane (ultrafiltration cassette Omega PES from PALL). The peptides were concentrated 25-fold, diafiltrated against 10 volumes of 50 mM sodium phosphate at pH 7.6 and finally concentrated 2-fold. This sample constitutes the purified hydrolyzate.
[0100] The purified hydrolyzate was analyzed by SDS-PAGE. The profile shows that there are no residual proteins with molecular weights above 10 kDa.
[0101] The efficiency of the purification was controlled by size exclusion HPLC. A BioSep-SEC S2000 column was equilibrated with 50 mM Na.sub.2HPO.sub.4, 0.5% (w/v) SDS, pH 6.8 at a flow rate of 1 ml/min. The peptides were detected at 215 nm.
Example 3
Preparation of House Dust Mite (Dermatophagoides pteronyssinus) Peptides
Example 3.1
Protein extraction of House Dust Mite
[0102] Proteins from House Dust Mite were extracted by incubation in Phosphate Buffer Saline pH 7.4 during 1 h at room temperature under stirring. The solution was clarified and filtrated by adding Celite at 2% (w/v) and passing through a 0.45 μm PVDF filter. This sample constitutes the crude protein extract.
[0103] The crude protein extract seems to show the major allergens (Derp1, Derp2) which can be localized according to their molecular weight (25 kDa and 14 kDa respectively).
Example 3.2
Purification of Allergen Proteins from House Dust Mite
[0104] The purification was performed by: [0105] Trichloracetic acid precipitation
[0106] 10% (w/v) trichloracetic acid was added to the crude protein extract under stirring for 5 min at room temperature. The proteins were collected by centrifugation during 20 min at 10.000 g. [0107] First denaturation
[0108] After elimination of the supernatant, the pellet was resuspended in 8 M urea, 0.1 M Tris pH 7-8. The solution was incubated for 1 h at 37° C. after pH adjustment to 7.5 and addition of 80 mM DTT. [0109] Size exclusion chromatography on G25 resin column
[0110] The proteins from the denaturated extract were loaded on the column, and eluted with 2 M Urea, 0.1 M NaCl pH 9.0.
[0111] The presence of proteins was monitored by the measurement of the absorbance at 280 nm. [0112] Second denaturation
[0113] The denaturation occurred by incubation at 37° C. for 1 h in 4 M urea, 0.1 M NaCl and 40 mM TCEP with the pH adjusted to 2.5.
Example 3.3
Hydrolysis of the Denaturated Allergens for House Dust Mite
[0114] The denaturated protein mixture was previously diluted 2-fold with 10 mM HCl and acidified with HCl 6N to pH 2.0. The hydrolysis of proteins was conducted with 16 Eu.Ph.0 of pepsin per 100 mg for 1 h at 37° C.
Example 4
Evaluation of Peptide Safety and Efficacy
Example 4.1
Production of sIgG Following Mice Immunization
[0115] Several batches of hydrolyzed allergens were prepared according to examples 1 to 3.
[0116] Groups of 8-10 mice were immunized with 6 intraperitoneal injections of 100 μg of different batches of allergen fragments combined with alum at a weekly interval. As positive control, one group of mice was immunized with unhydrolyzed full length allergens (proteins). Kinetic of specific IgG antibody production was measured by ELISA up to Day 56.
[0117] Results for grass pollen allergen (Lolium perenne) fragments are shown in
Example 4.2
Antibody Reactivity Against Allergen Fragments
[0118] Serum from different groups of mice (as explained in example 4.1) was collected at Day 42 and evaluated for their reactivity against full length-allergens by Western Blotting analysis. Proteins were loaded on a SDS-polyacrylamide gel, submitted to electrophoresis and transferred on a PVDF membrane under electric field. The PVDF membrane was cut into pieces, one for each sample tested, and were incubated with the serum of one group of mice. Binding was detected by anti-mouse IgG coupled to biotin and revealed by streptavidin coupled to a fluorescent label (europium).
[0119]
Example 4.3
Allergenicity—Facilitated Antigen Binding (FAB)
[0120] The allergenicity of various batches of allergen product was evaluated by IgE-facilitated allergen binding to B-cells as described in Shamji, M. H. et al. The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J. Immunol. Methods 317, 71-9 (2006). Serum from allergic (GPA, n=8) and non-atopic (NAC, n=8) subjects were pre-incubated with increasing concentrations of various product for 1 h at 37° C., followed by addition of 1×10.sup.5 EBV-transformed B-cells to allergen-IgE mixture and were further incubated for 1 h at 4° C. The allergen IgE complexes was determined by polyclonal human anti-IgE PE-labelled antibody and acquired by FACS. Results are shown in
Example 4.4
Allergenicity—Basophil Activation Test (BAT)
[0121] Allergenicity of various allergen batches from grass pollen, peanut and house dust mite fragments was determined by basophil activation test and diamine oxidase by flow cytometry.
[0122] Whole blood from allergic (AP, n=16) and non-atopic (NAC, n=6) individuals was incubated with increasing concentrations of one batch of proteins (unhydrolyzed allergens) and different batches of allergen fragments. Basophil activation was measured using flow cytometric method of the expression of the CD63 marker on the cell membrane of activated cells. Results for grass pollen (Lolium perenne) allergen fragments are shown in
[0123] Results for peanut (Arachis hypogaea) allergen fragments are shown in
[0124]
[0125] Results for house dust mite (Dermatophagoides pteronyssinus) allergen fragments are shown in
Example 4.5
Immunogenicity—Induction of CD19.SUP.+.IL10.SUP.+ B-cells
[0126] Effect of allergen fragments and unhydrolyzed allergens (proteins) was assessed on PBMCs isolated from allergic (AP, n=16) and non-atopic (NAC, n=6) individuals using flow cytometry. PBMCs were stimulated with 0, 0.1, 0.3, 1, 3 & 10 pg/mL concentrations of allergen fragments or full length allergens for 72 hrs at 37° C. Cells were stimulated with PMA, Ionomycin and BFA (Brefeldin A) and incubated for a total of 5 hrs at 37° C. Following incubation, cells were immunostained with CD19 for 30 min at room temperature. Cells were fixed and permeabilized using Cytofix/cytoperm reagent for 20 min at 4° C. and immunostained with IL10 for 30 min. Cells were washed and resuspended in cell staining buffer before acquisition on the BD FACS Canto II instrument. Results are shown in
Example 4.6
Immunogenicity—Induction of CD19.SUP.+.CD27.SUP.+.IL10.SUP.+ B-cells
[0127] PBMCs isolated from allergic patients (AP, n=16) and non-atopic (NAC, n=6) individuals using flow cytometry. PBMCs were stimulated with different batches of peptide or native proteins at 0, 0.1, 0.3, 1, 3 & 10 μg/mL concentrations for 72 hrs at 37° C. Cells were stimulated with PMA, Ionomycin and BFA (Brefeldin A) and incubated for a total of 5 hrs at 37° C. Following incubation, cells were immunostained with CD19, CD27 for 30 min at room temperature. Cells were fixed and permeabilized using Cytofix/cytoperm reagent for 20 min at 4° C. and immunostained with IL10 for 30 min. Cells were washed and resuspended in cell staining buffer before acquisition on the BD FACS Canto II instrument.
[0128]
Example 4.7
Immunogenicity—Induction of CD19.SUP.+.CD5.SUP.+.CD38.SUP.hi.CD24.SUP.hi.IL10.SUP.+ B-cells
[0129] PBMCs isolated from allergic patients (AP, n=16) and non-atopic (NAC, n=6) individuals using flow cytometry. PBMCs were stimulated with different batches of peptides or native proteins at 0, 0.1, 0.3, 1, 3 & 10 μg/mL concentrations for 72 hrs at 37° C. Cells were stimulated with PMA, Ionomycin and BFA (Brefeldin A) and incubated for a total of 5 hrs at 37° C. Following incubation, cells were immunostained with CD19, CD5, CD38, CD24 for 30 min at room temperature. Cells were fixed and permeabilized using Cytofix/cytoperm reagent for 20 min at 4° C. and immunostained with IL10 for 30 min. Cells were washed and resuspended in cell staining buffer before acquisition on the BD FACS Canto II instrument.
[0130]
Example 4.8
Immunogenicity—Induction of CD19.SUP.+.CD5.SUP.+.CD38.SUP.int.CD24.SUP.int.IL10.SUP.+ B-cells
[0131] PBMCs isolated from allergic patients (GPA, n=16) and non-atopic (NAC, n=6) individuals using flow cytometry. PBMCs were stimulated with different peptide batches or native proteins at 0, 0.1, 0.3, 1, 3 & 10 μg/mL concentrations for 72 hrs at 37° C. Cells were stimulated with PMA, Ionomycin and BFA (Brefeldin A) and incubated for a total of 5 hrs at 37° C. Following incubation, cells were immunostained with CD19, CD5, CD38, CD24 for 30 min at room temperature. Cells were fixed and permeabilized using Cytofix/cytoperm reagent for 20 min at 4° C. and immunostained with IL10 for 30 min. Cells were washed and resuspended in cell staining buffer before acquisition on the BD FACS Canto II instrument.
[0132]